GlassScriptPhysician profile
Gabriel Johnson
NPI 1093340622
$784.53
in general payments reported to CMS, 2019-2025
14 companies · $252 in 2025
The $252 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $75.35 · 2023: $14.25 · 2024: $443 · 2025: $252.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $709.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $709.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $197.23 | 2021-2024 | Airsupra, Farxiga, Breztri |
| Lilly USA, LLC | $120.36 | 2024-2025 | Jardiance, Mounjaro, Zepbound |
| Novo Nordisk INC | $113.72 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Amgen INC. | $65.36 | 2024-2025 | Otezla, Repatha, Otezla |
| Exact Sciences Corporation | $50.56 | 2024-2025 | Cologuard Collection Kit |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $42.44 | 2024-2025 | Caplyta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $40.98 | 2024 | Ofev, Jardiance |
| Lundbeck LLC | $34.89 | 2024-2025 | Rexulti |
| Phathom Pharmaceuticals, INC. | $30.94 | 2024-2025 | Voquezna |
| Ultragenyx Pharmaceutical INC. | $22.59 | 2021 | |
| Corcept Therapeutics | $20.01 | 2025 | Korlym |
| Ardelyx, INC. | $17.29 | 2024 | Ibsrela |
| Bayer Healthcare Pharmaceuticals INC. | $14.72 | 2025 | |
| Merck Sharp & Dohme LLC | $13.44 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gabriel Johnson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.